The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs. The research is published March 21 in Microbiology Spectrum, a journal of the American Society for Microbiology.

In January 2021, Mindray Medical signed an AI cooperation framework agreement with Tencent AI Lab.

Moderna, Pfizer, and BioNTech are seeking FDA approval for a fourth dose of their respective COVID-19 vaccines.

The US Food and Drug Administration last week granted Emergency Use Authorization for a SARS-CoV-2 molecular test developed by Helix.

According to the information of the official website China Food and Drug Administration, in March 18th, the 3 Shanghai COVID-19 antigen detection reagent products were approved.Up to now, China Food and Drug Administration has approved 17 COVID-19 antigen detection reagents.

BioMérieux said on Friday that it has received 510(k) clearance from the US Food and Drug Administration for its Vitek MS Prime MALDI-TOF mass spectrometry identification system.

The US Food and Drug Administration last week granted separate Emergency Use Authorizations for two SARS-CoV-2 antigen tests developed by Siemens Healthineers.

On March 17th, NMPA has approved the 14th New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold method) produced by Zybio. Up to now, 14 COVID-19 antigen detection kits have been approved for sale.

Eurofins Viracor said on Thursday that it has acquired an exclusive license to a sequencing-based liquid biopsy technology developed at Cornell University for tracking tissue damage in COVID-19 and transplant patients.

Foundation Medicine said on Thursday that the US Food and Drug Administration has approved its FoundationOne CDx test as a companion diagnostic to identify non-small cell lung cancer patients with EGFR exon 19 deletions or exon 21 alterations for treatment with EGFR inhibitors.